AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00630539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Trial: NCT02293915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simulant of sodium oligo-mannurarate capsule
Trial: NCT02637960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One daily dose of placebo (matched to fedovapagon) for 12 weeks
Trial: NCT00448123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02107053
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron is routinely administered to dialysis patients worldwide to correct anemia
Trial: NCT04405336
Drug: women who will not receive tab block or PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no tab block or PCA will be given
Trial: NCT02483884
Drug: [68Ga]RM2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[68Ga\]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)
Trial: NCT00848497
Drug: Testim®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
Trial: NCT00848497
Drug: Viagra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viagra 25mg was the dose given to the patient which he started.
Trial: NCT02644018
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00910234
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
Trial: NCT00349336
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00349336
Drug: FOLFOX-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00696904
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, see arms for intervention description
Trial: NCT00696904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, see arms for intervention description
Trial: NCT02350361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03513588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, 0 mg, 14 days, every 12 hours
Trial: NCT00003336
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
Trial: NCT01768520
Drug: Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex~2. evening : 1 tab. of active Entelon 150mg
Trial: NCT01768520
Drug: Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex~2. evening : 1 tab. of placebo Entelon 150mg
Trial: NCT01768520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex~2. evening : 1 tab. of placebo Entelon 150mg
Trial: NCT01190982
Drug: LEP-ETU
RxNorm normalized name: rabies virus vaccine flury-lep strain Injection [RabAvert]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
Trial: NCT00419068
Drug: Migliol Placebo Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01253915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 sec/nostril up to 4 times to treat a migraine
Trial: NCT00722852
Drug: ketoprofen in Diractin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg (b.i.d.)
Trial: NCT00722852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg (b.i.d.)
Trial: NCT00343252
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once weekly, oral, 18 months
Trial: NCT00343252
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily, subcutaneous, 18 months
Trial: NCT02076178
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose, Opadry film-coating, white OY-S-28876
Trial: NCT02076178
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline 0.9% Sodium Chloride Injection
Trial: NCT00731120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine placebo-matching capsules
Trial: NCT00096720
Drug: levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03709420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule to match active drug
Trial: NCT03709420
Drug: FOR-6219
RxNorm normalized name: Gas for Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOR-6219 capsule
Trial: NCT01646437
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01712711
Drug: H.pylori eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
Trial: NCT03857256
Drug: CP105F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural Health Product
Trial: NCT03857256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet manufactured to mimic the CP105F beta-glucan
Trial: NCT02541760
Drug: Monteleukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml monteleukast daily for one month
Trial: NCT02077569
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
Trial: NCT02472769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water
Trial: NCT06448962
Drug: AD-2021
RxNorm normalized name: Fluad 2020-2021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT06448962
Drug: AD-2022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT06448962
Drug: AD-2021 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT06448962
Drug: AD-2022 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT04084496
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Trial: NCT04681027
Drug: Oxymorphone hydrochloride (HCl)
RxNorm normalized name: Oxymorphone Hydrochloride
DrugBank: Oxymorphone (DB01192)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opioid
Trial: NCT03872570
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous administration
Trial: NCT00690118
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, 18 months
Trial: NCT01493622
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
Trial: NCT01493622
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
Trial: NCT03143023
Drug: arginine toothpaste
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: acid neutralizer toothpaste
Trial: NCT04243278
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo PO for 6 months
Trial: NCT00352118
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous continuously on days 1-4.
Trial: NCT01743625
Drug: COV155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COV155 tablets
Trial: NCT01743625
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02862782
Drug: hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh)
RxNorm normalized name: ZOSTER VACCINE LIVE (OKA/MERCK)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01551212
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.
Trial: NCT01767909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
Trial: NCT00108446
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00190034
Drug: N-Acetylcysteine 600mg/tab
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02308046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03218241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous to mimic PRT064445
Trial: NCT02471833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given placebo to be taken orally once a day before bedtime, for a duration of 8 months.
Trial: NCT02850211
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
Trial: NCT02850211
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
Trial: NCT00002844
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily intravenous infusions of cyclophosphamide for two days,
Trial: NCT01171105
Drug: AZD5213
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution, multiple ascending doses
Trial: NCT01171105
Drug: Placebo to AZD5213
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02392780
Drug: Calcineurin inhibitor
RxNorm normalized name: Calcineurin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
Trial: NCT02598453
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
Trial: NCT00618293
Drug: Haemate HS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of Haemate (dosage dependent on body weight)
Trial: NCT00296244
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
Trial: NCT04079803
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablet
Trial: NCT00296244
Drug: Enteric-coated Mycophenolic acid (EC-MPA)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
Trial: NCT00158899
Drug: GW501516 oral tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00070434
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825mg/m2 BID, PO, daily
Trial: NCT03353350
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Trial: NCT02254525
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.
Trial: NCT00070434
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus + IV for 46 hrs on Day 1
Trial: NCT00070434
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2 IV 2 hour infusion on Day 1
Trial: NCT00070434
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg TID, PO daily
Trial: NCT02678117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01381497
Drug: Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)
RxNorm normalized name: sumatriptan and naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an observational study and patients were prescribed this medication before study start
Trial: NCT00052559
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04283331
Drug: Proparacaine Ophthalmic
RxNorm normalized name: proparacaine ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will have one eye randomized to receive a bandage contact lens soaked in anesthetic solution (proparacaine hydrochloride 0.5%) and the following eye will serve as a control and receive a bandage soft contact lens soaked in balanced salt solution, which is the current standard of care for PRK.
Trial: NCT01381497
Drug: Triptan monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
Trial: NCT03492996
Drug: LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a \[14C\]-LCB01-0371-tracer dose to healthy subjects
Trial: NCT01838876
Drug: Antidepressant Therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
Trial: NCT00110708
Drug: Oralgam (human immunoglobulin)
RxNorm normalized name: immunoglobulin A, human
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03006874
Drug: CJ-12420 100mg QD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
Trial: NCT03006874
Drug: CJ-12420 50mg QD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
Trial: NCT00628264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
Trial: NCT01866917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00565682
Drug: etoricoxib 120 mg
RxNorm normalized name: etoricoxib 120 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 120 mg, tablet, orally, OD
Trial: NCT00259103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01545336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg tablet to be taken 1 time daily
Trial: NCT01258049
Drug: Artemether Sublingual Spray
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
Trial: NCT04297592
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg oral tablet, 2 times daily for 7 days
Trial: NCT06696807
Drug: glucocorticosteroids and/or intravenous immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day
Trial: NCT02218008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Trial: NCT04323735
Drug: Culturelle 10 Billion CFU Capsule
RxNorm normalized name: Culturelle 10 Billion CFU Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day (Low dose) or twice daily for a total of four doses (High dose) according to randomization group.
Trial: NCT00666809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID p.o. for 12 weeks + 4 weeks follow-up
Trial: NCT00357851
Drug: Aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03178539
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: non steroidal anti-inflammatory drug
Trial: NCT03178539
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non steroidal anti-inflammatory drug
Trial: NCT01722110
Drug: Indomethacin Extended-Release Capsules USP 75 mg
RxNorm normalized name: indomethacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg tablet once a day
Trial: NCT00354029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isotonic saline
Trial: NCT02360345
Drug: ONX-0801
FDA approved: no
EMA approved: no
PMDA approved: no